OCRX—The loan is at least as palatable as the $25M underwritten equity offering I was expecting (assuming that the interest rate is commensurate with the other terms of the deal).
OCRX still needs a partner in order to develop both the IV and oral formulations of OCR-002, but the new loan gives OCRX a little more flexibility in crafting a deal.
News 
Market Data 
Discover 
